Multicentre Paediatric Acceptability Study for Cyclophosphamide Powder
Multicentre Paediatric Acceptability Study for Cyclophosphamide Powder
From Study Execution to EMA Success A Global Phase III Program for Ranibizumab - Ophthalmic Biosimilar - Lambda CRO
From Study Execution to EMA Success A Global Phase III Program for Ranibizumab – Ophthalmic Biosimilar
International Clinical Trials Day 2026 - Lambda Therapeutic Research CRO
From Research to Real-World Impact: Lambda’s Journey on International Clinical Trials Day
Every year on 20 May, the global clinical research community observes International Clinical Trials Day, a moment to recognize the scientific progress, collaboration, and patient participation that make medical advancement…
Unannounced US-FDA inspection concludes with Zero 483 at Lambda's Ahmedabad Facility
Unannounced US FDA inspection concludes with Zero 483 at Lambda’s Ahmedabad Facility
NEWS
Biotherapeutics & Large Molecule Bioanalytical Services
Biotherapeutics & Large Molecule Bioanalytical Services
Lambda Therapeutic Research provides comprehensive bioanalytical services for biotherapeutics and large molecules, supporting biologic and biosimilar programs across preclinical and clinical development. With extensive experience in large molecule bioanalysis, we…
Transdermal and Topical Products Early Phase BA BE Study Capabilities Lambda CRO
Transdermal and Topical Products: Early Phase BA BE Study Capabilities
Lambda conducts early phase BA/BE studies for transdermal and topical products with a focus on pharmacokinetics, adhesion performance, and skin safety. Experience spans multiple molecules and dosage forms, supported by controlled application techniques and consistent study execution.
Lambda’s Clinical Laboratory, Ahmedabad - Consistently CAP accredited since 2005
CAP Accreditation Extended till 01 March 2028, Marking Continuous Compliance Since 2005
NEWS
Accelerated Study Start for BABE Programs in India with CDSCO Prior Intimation Pathway (CT-05) Lambda CRO
Accelerated Study Start for BA/BE Programs in India with CDSCO Prior Intimation Pathway (CT-05)
The regulatory environment in 2025 was defined by consolidation, clarification, and higher expectations for execution. Across major regions, regulators focused on improving trial quality, reducing avoidable administrative burden, and enabling scientific progress while maintaining patient safety and data integrity.
FDA Launches Framework to Accelerate Individualized Therapies for Ultra-Rare Diseases
FDA Launches Framework to Accelerate Individualized Therapies for Ultra-Rare Diseases
The agency's new "Plausible Mechanism Framework" creates a first-of-its-kind regulatory pathway for genome editing and RNA-based therapies targeting small patient populations where traditional clinical trials are not feasible. The U.S.…
World Cancer Day - Patient-Centric Oncology Clinical Trials in Advancing Cancer Research - Lambda CRO
Patient-Centric Trials in Advancing Cancer Research: A Journey of Progress & Hope
On World Cancer Day, we recognize the importance of cancer research in expanding early access to investigational therapies and generating evidence that informs progress in oncology care. At Lambda Therapeutic…
- 1
- 2
- 3
- 4
- …
- 14
- Go to the next page